A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive). Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The number of visits will be 9.

NCT Number	NCT07053423
Lead Sponsor	Sanofi Collaborators: Regeneron Pharmaceuticals
Conditions	Chronic Obstructive Pulmonary Disease
Enrollment	218 participants
Start Date	2025-09-22
Primary Completion	2028-12-23 (estimated)
Study Completion	2029-02-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-12